Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review.

Acute HIV infection HIV testing algorithms immediate antiretroviral therapy indeterminate HIV test post-exposure prophylaxis pre-exposure prophylaxis

Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
12 2019
Historique:
received: 11 06 2019
accepted: 22 10 2019
entrez: 19 12 2019
pubmed: 19 12 2019
medline: 5 6 2020
Statut: ppublish

Résumé

Knowledge of HIV status relies on accurate HIV testing, and is the first step towards access to HIV treatment and prevention programmes. Globally, HIV-status unawareness represents a significant challenge for achieving zero new HIV infections and deaths. In order to enhance knowledge of HIV status, the World Health Organisation (WHO) recommends a testing strategy that includes the use of HIV-specific antibody point-of-care tests (POCT). These POCTs do not detect acute HIV infection, the stage of disease when viral load is highest but HIV antibodies are undetectable. Complicating things further, in the presence of antiretroviral therapy (ART) for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP), other currently available testing technologies, such as viral load detection for diagnosis of acute HIV infection, may yield false-negative results. In this scoping review, we evaluate the evidence and discuss alternative HIV testing algorithms that may mitigate diagnostic dilemmas in the setting of increased utilization of ART for immediate treatment and prevention of HIV infection. Missed acute HIV infection prevents people living with HIV (PLHIV) from accessing early treatment, increases likelihood of onward transmission, and allows for inappropriate initiation or continuation of PrEP, which may result in HIV drug resistance. While immediate ART is recommended for all PLHIV, studies have shown that starting ART in the setting of acute HIV infection may result in a delayed or complete absence of development of HIV-specific antibodies, posing a diagnostic challenge that is particularly pertinent to resource-limited, high HIV burden settings where HIV-antibody POCTs are standard of care. Similarly, ART used as PrEP or PEP may supress HIV RNA viral load, complicating current HIV testing algorithms in resource-wealthy settings where viral detection is included. As rollout of PrEP continues, HIV testing algorithms may need to be modified. With increasing use of PrEP and ART in acute infection we anticipate diagnostic challenges using currently available HIV testing strategies. Research and surveillance are needed to determine the most appropriate assays and optimal testing algorithms that are accurate, affordable and sustainable.

Identifiants

pubmed: 31850686
doi: 10.1002/jia2.25419
pmc: PMC6918508
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25419

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NIAID NIH HHS
ID : R01 AI124968
Pays : United States
Organisme : PEPFAR
Pays : United States
Organisme : Wellcome Trust
ID : 107752/Z/15/Z
Pays : United Kingdom

Informations de copyright

© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

AIDS. 2003 Sep 5;17(13):1871-9
pubmed: 12960819
AIDS. 2015 Apr 24;29(7):793-800
pubmed: 25985402
Sex Transm Infect. 2018 Aug;94(5):331-333
pubmed: 28062734
PLoS Pathog. 2013 Mar;9(3):e1003211
pubmed: 23516360
J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):272-80
pubmed: 26428231
J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):e11-e13
pubmed: 29481487
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
Cochrane Database Syst Rev. 2014 Jan 21;(1):CD009593
pubmed: 24448973
N Engl J Med. 2019 Jul 18;381(3):207-218
pubmed: 31314965
Lancet HIV. 2018 Oct;5(10):e588-e596
pubmed: 30193863
Lancet HIV. 2017 Nov;4(11):e522-e528
pubmed: 28919303
J Int AIDS Soc. 2019 Dec;22(12):e25419
pubmed: 31850686
J Infect Dis. 2005 May 1;191(9):1403-9
pubmed: 15809897
J Infect Dis. 2010 Oct 15;202 Suppl 2:S270-7
pubmed: 20846033
PLoS One. 2014 Apr 08;9(4):e94062
pubmed: 24714441
Curr Opin HIV AIDS. 2016 Jan;11(1):49-55
pubmed: 26633640
N Engl J Med. 2016 Jun 2;374(22):2120-30
pubmed: 27192360
JAMA. 2018 Jul 24;320(4):379-396
pubmed: 30043070
Lancet. 2011 Jul 16;378(9787):256-68
pubmed: 21684591
J Clin Microbiol. 2019 Sep 24;57(10):
pubmed: 31217270
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):e52-e57
pubmed: 28902680
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
PLoS Med. 2013 Dec;10(12):e1001568; discussion e1001568
pubmed: 24339751
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
PLoS Med. 2012;9(7):e1001245
pubmed: 22802730
N Engl J Med. 2017 Feb 2;376(5):501-502
pubmed: 28146652
Clin Infect Dis. 2018 Aug 31;67(6):962-964
pubmed: 29961859
J Infect Dis. 2012 Feb 15;205(4):528-34
pubmed: 22207651
J Infect Dis. 2015 Jun 1;211(11):1757-60
pubmed: 25542958
J Med Ethics. 2018 Apr;44(4):270-276
pubmed: 29127137
Lancet Infect Dis. 2015 Jul;15(7):803-9
pubmed: 26043884
J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):e104-e106
pubmed: 29076941
Nat Rev Immunol. 2010 Jan;10(1):11-23
pubmed: 20010788
Sex Transm Infect. 2017 Mar;93(2):100-101
pubmed: 27272704
Open Forum Infect Dis. 2018 Jul 21;5(8):ofy180
pubmed: 30568989
Sci Transl Med. 2017 Dec 13;9(420):
pubmed: 29237762
Lancet HIV. 2018 Jan;5(1):e35-e44
pubmed: 28978417
AIDS. 2017 Sep 10;31(14):2007-2016
pubmed: 28692542
Lancet. 2009 Jan 3;373(9657):48-57
pubmed: 19038438
J Clin Virol. 2012 May;54(1):42-7
pubmed: 22381919
J Infect Dis. 2008 Sep 1;198(5):687-93
pubmed: 18662132
J Infect Dis. 2017 Aug 1;216(3):382-386
pubmed: 28666370
Clin Infect Dis. 2016 Aug 15;63(4):555-61
pubmed: 27317797
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
AIDS. 2015 Dec;29 Suppl 3:S221-30
pubmed: 26562811
PLoS Med. 2015 Mar 17;12(3):e1001801
pubmed: 25781323
J Clin Microbiol. 2016 Aug;54(8):2104-8
pubmed: 27252459
J Infect Dis. 2012 Dec 15;206(12):1947-9; author reply 1949-50
pubmed: 23045627
N Engl J Med. 2013 Jan 17;368(3):218-30
pubmed: 23323898
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
Int J STD AIDS. 2014 Sep;25(10):695-704
pubmed: 24759563
J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):271-279
pubmed: 28328548
J Clin Microbiol. 2014 Oct;52(10):3743-8
pubmed: 25122853
J Clin Virol. 2017 Sep;94:15-21
pubmed: 28710996
AIDS. 2016 Jul 31;30(12):1973-83
pubmed: 27149090
Nat Med. 2018 Jul;24(7):923-926
pubmed: 29892063
J Int AIDS Soc. 2017 Jun 28;20(1):21579
pubmed: 28691435
Open Forum Infect Dis. 2018 Sep 26;5(9):ofy197
pubmed: 30276221
Nat Commun. 2019 May 1;10(1):2005
pubmed: 31043606
Bull World Health Organ. 2012 Dec 1;90(12):914-20
pubmed: 23284197
AIDS. 2007 Oct 18;21(16):2237-42
pubmed: 18090052
AIDS. 2015 Nov 28;29(18):2465-71
pubmed: 26558545

Auteurs

Tamara Elliott (T)

Imperial College London, London, United Kingdom.
Imperial College Healthcare NHS Trust, London, United Kingdom.

Eduard J Sanders (EJ)

Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Meg Doherty (M)

Department of HIV and Global Hepatitis Programme, WHO, Geneva, Switzerland.

Thumbi Ndung'u (T)

Africa Health Research Institute, Durban, South Africa.
HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.
The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Max Planck Institute for Infection Biology, Berlin, Germany.

Myron Cohen (M)

Department of Internal Medicine, Division of Infectious Diseases, UNC School of Medicine, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.

Pragna Patel (P)

Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Gus Cairns (G)

NAM Aidsmap, London, United Kingdom.
PrEP in Europe Initiative, London, United Kingdom.

Sarah E Rutstein (SE)

Department of Internal Medicine, Division of Infectious Diseases, UNC School of Medicine, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.

Jintanat Ananworanich (J)

U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.

Colin Brown (C)

National Infection Service, Public Health England, London, United Kingdom.
Department of Infection, Royal Free London NHS Foundation Trust, London, United Kingdom.

Sarah Fidler (S)

Imperial College London, London, United Kingdom.
Imperial College NIHR BRC, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH